Chromogranin-A-Derived Peptides and Periodontitis in Diabetic Patients

This study is currently recruiting participants.

Verified by University Hospital, Strasbourg, France, January 2009

First Received: November 14, 2006 Last Updated: January 9, 2009 History of Changes

Sponsored by:	University Hospital, Strasbourg, France
Information provided by:	University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:	NCT00399620

Purpose

Periodontitis is a chronic disease of the supporting tissue of the teeth, characterized by bleeding and inflamed gingival, resorption of alveolar bone.

This disease has a significant impact of the quality of life as the teeth become progressively mobile and may fall out spontaneously if no treatment is provided. Periodontal disease has been cited as the sixth complication of diabetes mellitus.Chromogranins / secretogranins are a family of proteins present in nervous endocrine and immune cells, released with catecholamines during stress situations. Chromogranin A (CGA) is the major member of this family.The aim of this study is to determine the level of CGA and its derived peptides in the gingival crevicular fluid (GCF) of health or diabetic patients with and without periodontitis.Then, we want to determine the antimicrobial activity of these peptides.

Condition	Intervention
Periodontitis and Diabetitis	Procedure: Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title:	Chromogranin-A-Derived Peptides in the Gingival Crevicular Fluid and the Saliva of Diabetic Patients With or Without Periodontitis

Further study details as provided by University Hospital, Strasbourg, France:

Estimated Enrollment:	90
Study Start Date:	March 2008

Eligibility

Ages Eligible for Study:	20 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion criteria:

Patients from 20 to 80 years old
A minimum of 10 teeth
Healthy volunteers or diabetic patients with or without periodontitis

Exclusion criteria:

a course of antibiotics
a fungicidal therapy
a corticotherapy
a hormone therapy
a pregnancy
persons under guardianship

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00399620

Contacts

Contact: Martine Soell, MD

33 6 74 86 67 36

martine.soell@chru-strasbourg.fr

Locations

France
Département de Parodontologie - Hôpital Civil	Recruiting
Strasbourg, France, 67091
Contact: Martine Soell, MD 33.6.74.86.67.36 martine.soell@chru-strasbourg.fr
Principal Investigator: Martine Soell, MD
Sub-Investigator: Frédéric Blickle, MD

Sponsors and Collaborators

University Hospital, Strasbourg, France

Investigators

Study Director:

Martine Soell, MD

Hôpitaux Universitaires de Strasbourg

More Information

No publications provided

Study ID Numbers:	3739
Study First Received:	November 14, 2006
Last Updated:	January 9, 2009
ClinicalTrials.gov Identifier:	NCT00399620 History of Changes
Health Authority:	France: Ministry of Health

Keywords provided by University Hospital, Strasbourg, France:

Periodontitis
Diabetes
Gingival crevicular fluid
GCF
Saliva

Chromogranin
Electrophorèse
Western Blot
RT-HPLC

Study placed in the following topic categories:

Mouth Diseases
Periodontal Diseases
Periodontitis
Diabetes Mellitus
Stomatognathic Diseases

Additional relevant MeSH terms:

Mouth Diseases
Periodontal Diseases
Periodontitis
Stomatognathic Diseases

ClinicalTrials.gov processed this record on May 07, 2009